p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 201–300 of 1,031
Photochemoprevention of ultraviolet B signaling and photocarcinogenesis
Afaq, F., Adhami, V. M., & Mukhtar, H. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.07.019 · Cited by 310
p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes.
Long, X., Boluyt, M. O., Hipolito, M. L., Lundberg, M. S., Zheng, J. S., O'Neill, L., Cirielli, C., Lakatta, E. G., & Crow, M. T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119452 · Cited by 307
“These studies have led to the concept of p53 as guardian of the genome (26), its activation leading to either the cessation of DNA replication (growth arrest) long enough to repair genomic DNA or to the death of the cell in order to prevent damageinduced mutations from being incorporated into the genome.”
BackgroundVan Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H.-J., de Tribolet, N., & Cavenee, W. K. (1994) · Nature Genetics · doi:10.1038/ng1094-171 · Cited by 307
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
Pharoah, P. D. P., Day, N. E., & Caldas, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690628 · Cited by 308
“The curren accepted model for the function of the wild-type p53 protein i a multi-functional transcription factor involved in the control cell cycle progression, DNA integrity and cell survival in ce exposed to DNA-damaging agents (Lane, 1992).”
BackgroundHigh-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR
Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., & Gronenborn, A. M. (1994) · Science · doi:10.1126/science.8023159 · Cited by 307
Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy
Sifuentes-Franco, S., Padilla-Tejeda, D. E., Carrillo-Ibarra, S., & Miranda-Díaz, A. G. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1875870 · Cited by 300
Urothelial lesions in Chinese-herb nephropathy
Cosyns, J.-P., Jadoul, M., Squifflet, J.-P., Wese, F.-X., & van Ypersele de Strihou, C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70136-8 · Cited by 306
Bezzi, M., Teo, S. X., Muller, J., Mok, W. C., Sahu, S. K., Vardy, L. A., Bonday, Z. Q., & Guccione, E. (2013) · Genes & Development · doi:10.1101/gad.219899.113 · Cited by 300
“…sure that the addition of OHT or tamoxifen (TAM) was not toxic (data not shown). p53 is a transcription factor that drives the expression of several downstream targets in response to a variety of GENES & DEVELOPMENT 1905 stimuli, including activation of the DNA damage response (DDR) (Lane 1992).”
BackgroundInfluentialSun, Z., Fay, D. S., Marini, F., Foiani, M., & Stern, D. F. (1996) · Genes & Development · doi:10.1101/gad.10.4.395 · Cited by 300
“p53, the most frequently mutated tumor suppressor gene, is required for damage-regulated arrest at the G1/S checkpoint (Lane 1992).”
BackgroundSpecific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., & Vousden, K. H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00418.x · Cited by 301
Lotem, J., & Sachs, L. (1993) · Blood · doi:10.1182/blood.v82.4.1092.1092 · Cited by 301
Shaulian, E., Schreiber, M., Piu, F., Beeche, M., Wagner, E. F., & Karin, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00193-8 · Cited by 295
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
“Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.”
BackgroundSmall-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 283
Effect of p21WAF1/CIP1 Expression on Tumor Progression in Bladder Cancer
Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1072 · Cited by 299
The molecular basis for cell cycle delays following ionizing radiation: a review
Maity, A., McKenna, W. G., & Muschel, R. J. (1994) · Radiotherapy and Oncology · doi:10.1016/0167-8140(94)90408-1 · Cited by 294
Tumor suppressor genes and ROS: complex networks of interactions
Vurusaner, B., Poli, G., & Basaga, H. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.09.035 · Cited by 293
Sex steroidal regulation of uterine leiomyoma growth and apoptosis
Maruo, T. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh019 · Cited by 294
“Therefore, p53 has been categorized as both a caretaker and gatekeeper tumour suppressor gene (Lane, 1992).”
BackgroundValente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
The human MDM-2 oncogene is overexpressed in leukemias
Bueso-Ramos, C., Yang, Y., deLeon, E., McCown, P., Stass, S., & Albitar, M. (1993) · Blood · doi:10.1182/blood.v82.9.2617.2617 · Cited by 291
Lang, F. F., Miller, D. C., Koslow, M., & Newcomb, E. W. (1994) · Journal of Neurosurgery · doi:10.3171/jns.1994.81.3.0427 · Cited by 300
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53
Sugrue, M. M., Shin, D. Y., Lee, S. W., & Aaronson, S. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9648 · Cited by 292
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288
Control of the cell cycle and apoptosis
Weinberg, R. A., & Lundberg, A. S. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00046-5 · Cited by 285
Negative feedback regulation of wild-type p53 biosynthesis.
Mosner, J., Mummenbrauer, T., Bauer, C., Sczakiel, G., Grosse, F., & Deppert, W. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00123.x · Cited by 286
Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells.
Lowe, S. W., Jacks, T., Housman, D. E., & Ruley, H. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2026 · Cited by 287
Regulation and Significance of Apoptosis in the Stem Cells of the Gastrointestinal Epithelium
Potten, C. S., Wilson, J. W., & Booth, C. (1997) · STEM CELLS · doi:10.1002/stem.150082 · Cited by 287
Cell Death by Apoptosis in Epidermal Biology
Haake, A. R., & Polakowska, R. R. (1993) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12363594 · Cited by 288
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
“As ‘‘guardian of the genome,’’ p53 prevents the emergence of genetically variant clones by activating defense mechanisms, such as induction of senescent-like arrest and apoptotic programs, to prevent replication of defective cells (Lane, 1992; Vogelstein et al., 2000).”
Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage
Cox, L. S., & Lane, D. P. (1995) · BioEssays · doi:10.1002/bies.950170606 · Cited by 287
Self-citationHarris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 285
Genetic background alters the spectrum of tumors that develop in p53‐deficient mice
Harvey, M., McArthur, M. J., Montgomery, C. A., Bradley, A., & Donehower, L. A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344491 · Cited by 285
Strategies for global control of cervical cancer
Pontén, J., Adami, H., Bergström, R., Dillner, J., Friberg, L., Gustafsson, L., Miller, A. B., Parkin, D. M., Sparén, P., & Trichopoulos, D. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600102 · Cited by 289
Allegra, C. J., Paik, S., Colangelo, L. H., Parr, A. L., Kirsch, I., Kim, G., Klein, P., Johnston, P. G., Wolmark, N., & Wieand, H. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.044 · Cited by 282
Fusenig, N. E., & Boukamp, P. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199811)23:3<144::aid-mc3>3.0.co;2-u · Cited by 284
Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.
Yew, P. R., Liu, X., & Berk, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.2.190 · Cited by 283
The convergence of radiation and immunogenic cell death signaling pathways
Golden, E. B., Pellicciotta, I., Demaria, S., Barcellos-Hoff, M. H., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00088 · Cited by 282
“When this happens, the tumor cells accumulate DNA mutations, become aneuploid, and develop micronuclei, leading to MC and subsequent cell death (Lane, 1992).”
BackgroundApoptosis and hepatobiliary disease
Patel, T., & Gores, G. J. (1995) · Hepatology · doi:10.1002/hep.1840210635 · Cited by 264
Molecular principles of cancer invasion and metastasis (Review)
Efferth (2009) · International Journal of Oncology · doi:10.3892/ijo_00000214 · Cited by 279
Brugarolas, J., Moberg, K., Boyd, S. D., Taya, Y., Jacks, T., & Lees, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.3.1002 · Cited by 276
Dumaz, N., Drougard, C., Sarasin, A., & Daya-Grosjean, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10529 · Cited by 279
Cytoplasmic Sequestration of Wild-Type p53 Protein Impairs the G 1 Checkpoint after DNA Damage
Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M., & Zambetti, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1126 · Cited by 277
“In view of our findings, the most attractive explanation for these observations is that NB cells lack the G1 checkpoint as a result of p53 inactivation (sequestration), therefore rapidly accumulating and propagating mutagenic lesions that lead to mitotic failure and (nonapoptotic) cell death (30).”
BackgroundHernandez, L., Fest, T., Cazorla, M., Teruya-Feldstein, J., Bosch, F., Peinado, M., Piris, M., Montserrat, E., Cardesa, A., Jaffe, E., et al. (1996) · Blood · doi:10.1182/blood.v87.8.3351.bloodjournal8783351 · Cited by 275
p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer.
Bakalkin, G., Yakovleva, T., Selivanova, G., Magnusson, K. P., Szekely, L., Kiseleva, E., Klein, G., Terenius, L., & Wiman, K. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.413 · Cited by 275
Li, M., Zhang, Z., Hill, D. L., Wang, H., & Zhang, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3066 · Cited by 274
Cell-cycle control and its watchman
Jacks, T., & Weinberg, R. A. (1996) · Nature · doi:10.1038/381643a0 · Cited by 274
Stage-specific sensitivity to p53 restoration during lung cancer progression
Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Sanchez-Rivera, F. J., Resnick, R., Bronson, R., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 273
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
“All these studies have led to the proposal that p53 is a key element in the control of genome stability [Lane, 1992].”
BackgroundInteractions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271
Human Gene Mutation Database?A biomedical information and research resource
Krawczak, M., Ball, E. V., Fenton, I., Stenson, P. D., Abeysinghe, S., Thomas, N., & Cooper, D. N. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<45::aid-humu10>3.0.co;2-t · Cited by 273
Vennin, C., Mélénec, P., Rouet, R., Nobis, M., Cazet, A. S., Murphy, K. J., Herrmann, D., Reed, D. A., Lucas, M. C., Warren, S. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10968-6 · Cited by 268
Kerr, J. B., Hutt, K. J., Michalak, E. M., Cook, M., Vandenberg, C. J., Liew, S. H., Bouillet, P., Mills, A., Scott, C. L., Findlay, J. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.017 · Cited by 263
“Trp53, the so-called ‘‘guardian of the genome’’ (Lane, 1992), exerts its tumor suppressor function in part (in at least certain contexts, such as deregulated MYC expression) through activation of apoptosis, and this requires transcriptional induction of the BH3-only proapoptotic BCL-2 family…”
American Joint Committee on Cancer Prognostic Factors Consensus Conference
Yarbro, J. W., Page, D. L., Fielding, L. P., Partridge, E. E., & Murphy, G. P. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11<2436::aid-cncr35>3.0.co;2-# · Cited by 266
Chen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E. R., Hill, D. L., Wang, H., & Zhang, R. (2007) · Oncogene · doi:10.1038/sj.onc.1210327 · Cited by 261
Solution structure of the tetrameric minimum transforming domain of p53
Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., & Arrowsmith, C. H. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-877 · Cited by 265
PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE
STEIN, J. P., GROSSFELD, G. D., GINSBERG, D. A., ESRIG, D., FREEMAN, J. A., FIGUEROA, A. J., SKINNER, D. G., & COTE, R. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62747-2 · Cited by 271
Harrington, E. A., Fanidi, A., & Evan, G. I. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90100-7 · Cited by 265
Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin
Han, Z., Wei, W., Dunaway, S., Darnowski, J. W., Calabresi, P., Sedivy, J., Hendrickson, E. A., Balan, K. V., Pantazis, P., & Wyche, J. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112401200 · Cited by 262
Jones, D. L., Thompson, D. A., & Münger, K. (1997) · Virology · doi:10.1006/viro.1997.8851 · Cited by 231
Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches
Fania, L., Didona, D., Di Pietro, F. R., Verkhovskaia, S., Morese, R., Paolino, G., Donati, M., Ricci, F., Coco, V., Ricci, F., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9020171 · Cited by 255
The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation
Esser, C., Scheffner, M., & Höhfeld, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501574200 · Cited by 261
Leonova, K. I., Brodsky, L., Lipchick, B., Pal, M., Novototskaya, L., Chenchik, A. A., Sen, G. C., Komarova, E. A., & Gudkov, A. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216922110 · Cited by 261
Genetic pathways in colorectal and other cancers
Ilyas, M., Straub, J., Tomlinson, I. P. M., & Bodmer, W. F. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00431-6 · Cited by 257
Sukumar, U. K., Bose, R. J. C., Malhotra, M., Babikir, H. A., Afjei, R., Robinson, E., Zeng, Y., Chang, E., Habte, F., Sinclair, R., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119342 · Cited by 251
Photocarcinogenesis: an overview
Black, H. S., deGruijl, F. R., Forbes, P. D., Cleaver, J. E., Ananthaswamy, H. N., deFabo, E. C., Ullrich, S. E., & Tyrrell, R. M. (1997) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(97)00021-3 · Cited by 260
Folpe, A. L., Lyles, R. H., Sprouse, J. T., Conrad, E. U., & Eary, J. F. (2000) · PubMed · Cited by 257
Milne, D. M., Campbell, L. E., Campbell, D. G., & Meek, D. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5511 · Cited by 257
p53 induction is associated with neuronal damage in the central nervous system.
Sakhi, S., Bruce, A., Sun, N., Tocco, G., Baudry, M., & Schreiber, S. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7525 · Cited by 259
Houbiers, J. G. A., Nijman, H. W., Van Der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van De Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., & Melief, C. J. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230905 · Cited by 258
(1997) · PubMed · Cited by 256
Li, P.-X., Wong, J., Ayed, A., Ngo, D., Brade, A. M., Arrowsmith, C., Austin, R. C., & Klamut, H. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909580199 · Cited by 254
Terphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 Interaction
Yin, H., Lee, G., Park, H. S., Payne, G. A., Rodriguez, J. M., Sebti, S. M., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462316 · Cited by 255
Hughes, P. E., Alexi, T., Walton, M., Williams, C. E., Dragunow, M., G. Clark, R., & Gluckman, P. D. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00057-4 · Cited by 253
“DNA damage is a strong inducer of p53 and it has been said that p53 functions to act as thèguardian of the genome' (Lane, 1992).”
BackgroundZinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts
Ho, E., Courtemanche, C., & Ames, B. N. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.8.2543 · Cited by 252
Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53
Tan, M., Li, S., Swaroop, M., Guan, K., Oberley, L. W., & Sun, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.12061 · Cited by 253
Packham, G., & Cleveland, J. L. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)00015-t · Cited by 245
Abid-Essefi, S., Ouanes, Z., Hassen, W., Baudrimont, I., Creppy, E., & Bacha, H. (2004) · Toxicology in Vitro · doi:10.1016/j.tiv.2003.12.011 · Cited by 249
Velasco-Miguel, S., Buckbinder, L., Jean, P., Gelbert, L., Talbott, R., Laidlaw, J., Seizinger, B., & Kley, N. (1999) · Oncogene · doi:10.1038/sj.onc.1202274 · Cited by 252
“The ability of p53 to inhibit cell growth in response to common cellular stresses such as hypoxia and DNA damage, is a major function associated with its role as a tumor suppressor and `guardian of the genome' (Lane, 1992).”
Backgroundp53 Protein Exhibits 3′-to-5′ Exonuclease Activity
Mummenbrauer, T., Janus, F., Müller, B., Wiesmüller, L., Deppert, W., & Grosse, F. (1996) · Cell · doi:10.1016/s0092-8674(00)81309-4 · Cited by 249
Apoptosis in Human Disease: A New Skin for the Old Ceremony?
Fadeel, B., Orrenius, S., & Zhivotovsky, B. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1888 · Cited by 249
Apoptosis in Target Organs of Hypertension
Hamet, P., Richard, L., Dam, T.-V., Teiger, E., Orlov, S. N., Gaboury, L., Gossard, F., & Tremblay, J. (1995) · Hypertension · doi:10.1161/01.hyp.26.4.642 · Cited by 249
The Hematologist and Radiation Casualties
Dainiak, N., Waselenko, J. K., Armitage, J. O., MacVittie, T. J., & Farese, A. M. (2003) · Hematology · doi:10.1182/asheducation-2003.1.473 · Cited by 245
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.
Illmer, T., Schuler, U. S., Thiede, C., Schwarz, U. I., Kim, R. B., Gotthard, S., Freund, D., Schäkel, U., Ehninger, G., & Schaich, M. A. (2002) · PubMed · Cited by 248
Nrf2, a Guardian of Healthspan and Gatekeeper of Species Longevity
Lewis, K. N., Mele, J., Hayes, J. D., & Buffenstein, R. (2010) · Integrative and Comparative Biology · doi:10.1093/icb/icq034 · Cited by 245
Thioredoxin and Its Role in Toxicology
Watson, W. H. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh050 · Cited by 247
“Because activation of p53 by genotoxic agents and oxidative stress results in cell-cycle arrest, upregulation of repair pathways, and the initiation of apoptosis if repair is not possible, p53 has been called the guardian of the genome (Lane, 1992).”
BackgroundThe WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.
Maheswaran, S., Englert, C., Bennett, P., Heinrich, G., & Haber, D. A. (1995) · Genes & Development · doi:10.1101/gad.9.17.2143 · Cited by 248
Zhao, Y., Chaiswing, L., Velez, J. M., Batinic-Haberle, I., Colburn, N. H., Oberley, T. D., & St. Clair, D. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3835 · Cited by 245
p53-dependent apoptosis suppresses radiation–induced teratogenesis
Norimura, T., Nomoto, S., Katsuki, M., Gondo, Y., & Kondo, S. (1996) · Nature Medicine · doi:10.1038/nm0596-577 · Cited by 247
Stengel, A., Kern, W., Haferlach, T., Meggendorfer, M., Fasan, A., & Haferlach, C. (2017) · Leukemia · doi:10.1038/leu.2016.263 · Cited by 242
Apoptosis induced by inhibition of intercellular contact.
Bates, R. C., Buret, A., van Helden, D. F., Horton, M. A., & Burns, G. F. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.2.403 · Cited by 248
“The p53 protein is a tumor suppressor gene product, with the wild-type able to negatively regulate cell proliferation by growth arrest in G1, to inhibit in vitro transformation, and also to suppress tumorigenesis (for review see Lane, 1992; Volgelstein and KJnzler, 1992).”
BackgroundFuchs, B., & Pritchard, D. J. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200204000-00007 · Cited by 248
p53 and its isoforms in cancer
Bourdon, J.-C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603886 · Cited by 245
“Hence, p53 protein is the guardian of the genome preventing cancer formation (Lane, 1992).”
BackgroundLin, K., Sherrington, P. D., Dennis, M., Matrai, Z., Cawley, J. C., & Pettitt, A. R. (2002) · Blood · doi:10.1182/blood-2001-11-0066 · Cited by 247
Understanding the Molecular Genetics of Basal Cell Carcinoma
Pellegrini, C., Maturo, M., Di Nardo, L., Ciciarelli, V., Gutiérrez García-Rodrigo, C., & Fargnoli, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112485 · Cited by 242
p53 in recombination and repair
Gatz, S. A., & Wiesmüller, L. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401903 · Cited by 242
“Soon after having established TP53 as the most frequently altered gene in human tumours in the 1990s,(1,2) p53 was understood as a major component of the DNA damage response pathway.(3,4) After the introduction of DNA injuries”
BackgroundHCV NS5A interacts with p53 and inhibits p53-mediated apoptosis
Lan, K.-H., Sheu, M.-L., Hwang, S.-J., Yen, S.-H., Chen, S.-Y., Wu, J.-C., Wang, Y.-J., Kato, N., Omata, M., Chang, F.-Y., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205589 · Cited by 245
“…Group All rights reserved 0950 – 9232/02 $25.00 www.nature.com/onc The tumor suppressor p53 protein is involved in the maintenance of genomic integrity (Lane, 1992), while activated p53 functions via its ability to transactivate gene expression and mediates its downstream events mainly by two…”
BackgroundInfluentialp53 and ribosome biogenesis stress: The essentials
Golomb, L., Volarevic, S., & Oren, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.014 · Cited by 242
The ups and downs of p53: understanding protein dynamics in single cells
Batchelor, E., Loewer, A., & Lahav, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2604 · Cited by 244
Carlson, J. A., Ambros, R., Malfetano, J., Ross, J., Grabowski, R., Lamb, P., Figge, H., & Mihm, M. C. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90198-8 · Cited by 248
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.